Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Fujirebio recently announced that the US Food and Drug Administration (FDA) has granted clearance for the company’s Lumipulse in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

New blood test approved for Alzheimer's diagnosis. The test measures two proteins in blood plasma, correlating with amyloid plaques in the brain.

A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has ...

A wave of diagnostic tests—some here, some coming—can identify cancer and Alzheimer’s at earlier stages and predict flare-ups ...

The US Food and Drug Administration (FDA) has approved the first blood test for diagnosing Alzheimer’s disease.1 The test, called Lumipulse, was granted breakthrough device approval and is designed ...

An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve ...

A highly sensitive real-time PCR-based systems helps scientists rapidly detect microbial contamination in cell therapy ...